New Forecasts: Here's What Analysts Think The Future Holds For Nanjing Leads Biolabs Co., Ltd. (HKG:9887)
Nanjing Leads Biolabs Co., Ltd. (HKG:9887) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The revenue forecast for this year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.
After this upgrade, Nanjing Leads Biolabs' four analysts are now forecasting revenues of CN¥231m in 2026. This would be a sizeable 30% improvement in sales compared to the last 12 months. The loss per share is expected to ameliorate slightly, reducing to CN¥1.02. However, before this estimates update, the consensus had been expecting revenues of CN¥199m and CN¥1.13 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.
Check out our latest analysis for Nanjing Leads Biolabs
Despite these upgrades, the analysts have not made any major changes to their price target of CN¥86.07, implying that their latest estimates don't have a long term impact on what they think the stock is worth. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Nanjing Leads Biolabs, with the most bullish analyst valuing it at CN¥93.98 and the most bearish at CN¥68.23 per share. With such a narrow range of valuations, analysts apparently share similar views on what they think the business is worth.
The Bottom Line
The highlight for us was that the consensus reduced its estimated losses this year, perhaps suggesting Nanjing Leads Biolabs is moving incrementally towards profitability. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Nanjing Leads Biolabs.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Nanjing Leads Biolabs going out to 2028, and you can see them free on our platform here..
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.